Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection

Fidaxomicin, a macrocyclic antibiotic, selectively kills Clostridioides difficile and reduces C. difficile infection (CDI) recurrence compared with vancomycin, but some studies and guidelines report fidaxomicin as being less cost-effective. The aim of this study was to compare the cost-effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitney, Laura, Nesnas, John, Planche, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854770/
https://www.ncbi.nlm.nih.gov/pubmed/36671306
http://dx.doi.org/10.3390/antibiotics12010106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854770/
https://www.ncbi.nlm.nih.gov/pubmed/36671306
http://dx.doi.org/10.3390/antibiotics12010106

Ejemplares similares